Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T‐cell therapy.

Autor:	Nakamura, Naokazu, Arai, Yasuyuki, Kitawaki, Toshio, Jo, Tomoyasu, Mizumoto, Chisaki, Kanda, Junya, Nishikori, Momoko, Yamashita, Kouhei, Takaori‐Kondo, Akifumi
Předmět:	CYTOKINE release syndrome CHIMERIC antigen receptors HYPOPHOSPHATEMIA T cells DIFFUSE large B-cell lymphomas
Zdroj:	British Journal of Haematology; Jan2023, Vol. 200 Issue 1, pe1-e3, 3p
Abstrakt:	Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy Key sentences CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy is an innovative treatment[1] for patients with diffuse large B-cell lymphoma (DLBCL). Keywords: chimeric antigen receptor T cell (CAR-T); cytokine release syndrome (CRS); hypophosphataemia; predictive marker EN chimeric antigen receptor T cell (CAR-T) cytokine release syndrome (CRS) hypophosphataemia predictive marker e1 e3 3 12/22/22 20230101 NES 230101 Decreased serum iP can be a predictive marker for subsequent severe CRS. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text